--- title: "ATYR Pharma | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295273908.md" datetime: "2026-08-07T20:16:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295273908.md) - [en](https://longbridge.com/en/news/295273908.md) - [zh-HK](https://longbridge.com/zh-HK/news/295273908.md) generator: "portal-rs" --- # ATYR Pharma | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0, meeting the estimate of USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.11, beating the estimate of USD -0.125. EBIT: As of FY2026 Q2, the actual value is USD -10.31 M. ### Financial Highlights for aTyr Pharma, Inc. #### Cash and Investment Position As of June 30, 2026, cash, cash equivalents, restricted cash, and available-for-sale investments totaled $58,913 thousand, a decrease from $80,922 thousand as of December 31, 2025. The company anticipates this cash position will be sufficient to fund current operations into late 2028. #### Operating Expenses ##### Three Months Ended June 30 - **Research and Development (R&D) Expenses**: R&D expenses were $6,748 thousand for the second quarter of 2026, a decrease from $15,384 thousand in the second quarter of 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $4,133 thousand for the second quarter of 2026, down from $4,929 thousand in the second quarter of 2025. - **Total Operating Expenses**: Total operating expenses for the second quarter of 2026 were $10,881 thousand, compared to $20,313 thousand for the same period in 2025. ##### Six Months Ended June 30 - **Research and Development (R&D) Expenses**: R&D expenses were $14,065 thousand for the six months ended June 30, 2026, a decrease from $27,198 thousand for the same period in 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $8,252 thousand for the six months ended June 30, 2026, compared to $8,888 thousand for the same period in 2025. - **Total Operating Expenses**: Total operating expenses for the six months ended June 30, 2026, were $22,317 thousand, down from $36,086 thousand for the same period in 2025. #### Loss from Operations - **Three Months Ended June 30**: Loss from operations was -$10,881 thousand in the second quarter of 2026, an improvement from -$20,313 thousand in the second quarter of 2025. - **Six Months Ended June 30**: Loss from operations was -$22,317 thousand for the six months ended June 30, 2026, compared to -$36,086 thousand for the same period in 2025. #### Total Other Income (Expense), net - **Three Months Ended June 30**: Total other income (expense), net, was $571 thousand in the second quarter of 2026, compared to $781 thousand in the second quarter of 2025. - **Six Months Ended June 30**: Total other income (expense), net, was $1,215 thousand for the six months ended June 30, 2026, compared to $1,673 thousand for the same period in 2025. #### Consolidated Net Loss - **Three Months Ended June 30**: Consolidated net loss was -$10,310 thousand in the second quarter of 2026, an improvement from -$19,532 thousand in the second quarter of 2025. - **Six Months Ended June 30**: Consolidated net loss was -$21,102 thousand for the six months ended June 30, 2026, compared to -$34,413 thousand for the same period in 2025. #### Net Loss Attributable to aTyr Pharma, Inc. - **Three Months Ended June 30**: Net loss attributable to aTyr Pharma, Inc. was -$10,309 thousand in the second quarter of 2026, compared to -$19,531 thousand in the second quarter of 2025. - **Six Months Ended June 30**: Net loss attributable to aTyr Pharma, Inc. was -$21,100 thousand for the six months ended June 30, 2026, compared to -$34,411 thousand for the same period in 2025. #### Operational Metrics and Restructuring aTyr Pharma, Inc. implemented a corporate restructuring, including a workforce reduction of approximately 60%, to align resources with its efzofitimod program. This restructuring and additional cost-saving measures are expected to reduce annualized operating expenses by approximately $13 million, starting in the fourth quarter of 2026. #### Outlook and Guidance aTyr Pharma, Inc. is awaiting feedback from the FDA by the end of August 2026 on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis. Topline results from the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD are anticipated in the first quarter of 2027. The company will require additional capital through various financing means to fund the future development of efzofitimod in the planned Phase 3 study. ### Related Stocks - [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md) ## Related News & Research - [aTyr Pharma submits Phase 3 efzofitimod trial protocol to FDA for pulmonary sarcoidosis study](https://longbridge.com/en/news/295273060.md) - [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md) - [Valion Bio amends 8-K to report final vote tally on reverse stock split approval](https://longbridge.com/en/news/296531983.md) - [Lipocine 8-K/A adds Michael Grissinger to compensation committee](https://longbridge.com/en/news/296650509.md) - [Getty Realty amends 8-K to detail Eugene Shnayderman separation, including $300,000 cash payment](https://longbridge.com/en/news/296534890.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**